Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0...

Related Keywords

United States ,Canada ,American ,Billy Dunn ,Bristol Myers Squibb ,Development Collaboration ,European Medicines Agency ,Drug Administration ,Movement Disorders ,Global Neuroscience Research ,Nasdaq ,Exchange Commission ,Novo Nordisk ,Office Of Neuroscience ,Prothena Corporation ,International Congress ,Walgreens ,Company On Twitter Prothenacorp ,American Society Of Hematology ,Gene Kinney ,Chief Executive Officer ,Fast Track ,Bristol Myers ,Myers Squibb ,Mayo Stage ,Orphan Drug Designation ,European Medicines ,American Society ,Special Protocol Assessment ,Full Year ,Quarterly Report ,Annual Report ,Ended December ,Markets ,